Meeting
2019 ASCO Annual Meeting
FGFR2: A pan-genomic target.
Authors
Russell Madison
Foundation Medicine, Inc., Cambridge, MA
Russell Madison , Ethan Sokol , Alexa Betzig Schrock , Adrienne Johnson , Dean Pavlick , Julia Andrea Elvin , Jo-Anne Vergilio , Nhu Ngo , Jonathan Keith Killian , Douglas I. Lin , Shakti Ramkissoon , Eric Allan Severson , Amanda Hemmerich , Daniel Duncan , Siraj Mahamed Ali , Prasanth Reddy , Kimberly McGregor , Brian Alexander , Vincent A. Miller , Jeffrey S. Ross
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3099)
DOI
10.1200/JCO.2019.37.15_suppl.3099
Abstract #
3099
Poster Bd #
91
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).
First Author: Milind M. Javle
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis.
First Author: Steven Brad Maron
Poster
2019 ASCO Annual Meeting
Mutational landscapes and PD-L1 expression in non-small cell lung cancer.
First Author: Kang Zhang